Prime Medicine, Inc. (Nasdaq: PRME) announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)June 22, 2026 8:00 AM